Cargando…
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria
Plasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was th...
Autores principales: | St Jean, Pamela L., Koh, Gavin C.K.W., Breton, John J., Espino, Fe E.J., Hien, Tran T., Krudsood, Srivicha, Lacerda, Marcus V.G., Llanos-Cuentas, Alejandro, Lon, Chanthap, Mohammed, Rezika, Namaik-larp, Chayadol S., Pereira, Dhelio B., Saunders, David L., Velez, Ivan D., Yilma, Daniel, Villegas, Maria F., Duparc, Stephan, Green, Justin A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409770/ https://www.ncbi.nlm.nih.gov/pubmed/32433338 http://dx.doi.org/10.1097/FPC.0000000000000407 |
Ejemplares similares
-
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping
por: Beck, Hans-Peter, et al.
Publicado: (2016) -
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Llanos-Cuentas, A., et al.
Publicado: (2019) -
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis
por: Watson, James A, et al.
Publicado: (2022) -
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial
por: St Jean, Pamela L., et al.
Publicado: (2016) -
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria
por: Lacerda, M.V.G., et al.
Publicado: (2019)